Q-omics provides the consensus-scored USP12-AS2 profile across patient tissues and cancer cell-line models. USP12-AS2 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in THCA. Among the 18 cancer types available for tumor–normal comparison, USP12-AS2 is differentially expressed in 8, with the highest sampling consensus in KICH. Additionally, USP12-AS2 RNA expression shows 12,335 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight THCA, KICH, and TGCT as cancer lineages where USP12-AS2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for USP12-AS2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes USP12-AS2 survival associations across molecular data types. USP12-AS2 RNA expression shows survival associations in the most cancer types (23). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible USP12-AS2 RNA expression–survival associations across cancer types. High USP12-AS2 expression shows unfavorable associations in THCA, but favorable associations in PAAD, LUSC, MESO, UVM and STAD. The THCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify THCA as the clearest survival context for USP12-AS2 RNA expression.
This table summarizes USP12-AS2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in KICH for RNA.
This table ranks reproducible tumor–normal expression differences for USP12-AS2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. USP12-AS2 shows lower tumor expression in KICH, KIRP, KIRC and UCEC and higher tumor expression in LIHC and HNSC. The KICH box plot shows higher USP12-AS2 RNA expression in normal versus tumor tissue (log2 FC = −1.470, t-test p < 0.001).
This table shows molecular features associated with USP12-AS2 in patient tissues and cancer cell lines. In patient samples, USP12-AS2 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set.
